WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H318602
CAS#: 56-54-2 (free base)
Description: Quinidine (free base) is a dextrorotatory stereoisomer of quinine with antimalarial and antiarrhythmic properties.
Hodoodo Cat#: H318602
Name: Quinidine (free base)
CAS#: 56-54-2 (free base)
Chemical Formula: C20H24N2O2
Exact Mass: 324.18
Molecular Weight: 324.420
Elemental Analysis: C, 74.04; H, 7.46; N, 8.64; O, 9.86
Related CAS #: 747-45-5 (bisulfate) 27555-34-6 (polygalacturonate) 56-54-2 (free base) 1668-99-1 (HCl) 7054-25-3 (gluconate)
Synonym: Quinidine (free base); Chinidin; Pitayine; (+)-Quinidine; Quinidex; Chinidin; Fawns and McAllan Brand of Quinidine Sulfate; Nelson Brand of Quinidine Sulfate; Quincardine; Quinidex; Quinidine; Quinidine Sulfate; Quinora; Robins Brand of Quinidine Sulfate; Sulfate, Quinidine;
IUPAC/Chemical Name: (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol
InChi Key: LOUPRKONTZGTKE-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3
SMILES Code: COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 324.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Wang Q, Zhu P, Ruan M, Wu H, Peng K, Han H, Somsen GW, Crommen J, Jiang Z.
Chiral separation of acidic compounds using an O-9-(tert-butylcarbamoyl)quinidine
functionalized monolith in micro-liquid chromatography. J Chromatogr A. 2016 Apr
29;1444:64-73. doi: 10.1016/j.chroma.2016.03.047. Epub 2016 Mar 19. PubMed PMID:
27038701.
2: Ruan X. The Effect of Quinidine, a Strong P-Glycoprotein Inhibitor, on the
Pharmacokinetics and Central Nervous System Distribution of Naloxegol. J Clin
Pharmacol. 2016 Apr;56(4):506-7. doi: 10.1002/jcph.651. PubMed PMID: 26954552.
3: Al-Huniti N. Reply to: Letter to the Editor "Effect of Quinidine, a Strong
P-Glycoprotein Inhibitor, on the Pharmacokinetics and Central Nervous System
Distribution of Naloxegol". J Clin Pharmacol. 2016 Apr;56(4):508. doi:
10.1002/jcph.674. PubMed PMID: 26954553.
4: Bui K, She F, Zhou D, Butler K, Al-Huniti N, Sostek M. The effect of
quinidine, a strong P-glycoprotein inhibitor, on the pharmacokinetics and central
nervous system distribution of naloxegol. J Clin Pharmacol. 2016
Apr;56(4):497-505. doi: 10.1002/jcph.613. Epub 2015 Nov 9. PubMed PMID: 26248047.
5: Garcia-Baran D, Johnson TM, Wagner J, Shen J, Geers M. Therapeutic Approach of
a High Functioning Individual With Traumatic Brain Injury and Subsequent
Emotional Volatility With Features of Pathological Laughter and Crying With
Dextromethorphan/Quinidine. Medicine (Baltimore). 2016 Mar;95(12):e2886. doi:
10.1097/MD.0000000000002886. PubMed PMID: 27015166.
6: Cummings JL, Siffert J. Dextromethorphan-Quinidine for Agitation in Alzheimer
Disease--Reply. JAMA. 2016 Mar 15;315(11):1166-7. doi: 10.1001/jama.2015.18289.
PubMed PMID: 26978215.
7: Chong PF, Nakamura R, Saitsu H, Matsumoto N, Kira R. Ineffective quinidine
therapy in early onset epileptic encephalopathy with KCNT1 mutation. Ann Neurol.
2016 Mar;79(3):502-3. doi: 10.1002/ana.24598. Epub 2016 Feb 12. PubMed PMID:
26748457.
8: Newman JC, Steinman MA. Dextromethorphan-Quinidine for Agitation in Alzheimer
Disease. JAMA. 2016 Mar 15;315(11):1166. doi: 10.1001/jama.2015.18286. PubMed
PMID: 26978214.
9: Wu H, Wang Q, Ruan M, Peng K, Zhu P, Crommen J, Han H, Jiang Z.
Enantioseparation of N-derivatized amino acids by micro-liquid
chromatography/laser induced fluorescence detection using quinidine-based
monolithic columns. J Pharm Biomed Anal. 2016 Mar 20;121:244-52. doi:
10.1016/j.jpba.2015.12.011. Epub 2015 Dec 15. PubMed PMID: 26732881.
10: Turner J, Mitchell JL, Carroll BT, Denysenko L. Dextromethorphan/quinidine
withdrawal-emergent catatonia. Ann Clin Psychiatry. 2016 Feb 1;28(1):e8-e9. [Epub
ahead of print] PubMed PMID: 26855991.
11: Corbett A, Ballard C. Dextromethorphan and quinidine are suitable for
off-label short-term treatment of agitation in people with Alzheimer's disease
following first-line non-drug approaches. Evid Based Med. 2016 Feb;21(1):25. doi:
10.1136/ebmed-2015-110324. Epub 2015 Dec 23. PubMed PMID: 26701197.
12: Wang Q, Sánchez-López E, Han H, Wu H, Zhu P, Crommen J, Marina ML, Jiang Z.
Separation of N-derivatized di- and tri-peptide stereoisomers by micro-liquid
chromatography using a quinidine-based monolithic column - Analysis of
l-carnosine in dietary supplements. J Chromatogr A. 2016 Jan 8;1428:176-84. doi:
10.1016/j.chroma.2015.09.016. Epub 2015 Sep 8. PubMed PMID: 26410182.
13: Fukao M, Kondo E, Nishino H, Hattori R, Horie A, Hashimoto Y. Presence of an
H(+)/Quinidine Antiport System in Madin-Darby Canine Kidney Cells. Eur J Drug
Metab Pharmacokinet. 2015 Dec 1. [Epub ahead of print] PubMed PMID: 26628429.
14: Higgins AY, Waks JW, Josephson ME. Influence of Gender on the Tolerability,
Safety, and Efficacy of Quinidine Used for Treatment of Supraventricular and
Ventricular Arrhythmias. Am J Cardiol. 2015 Dec 15;116(12):1845-51. doi:
10.1016/j.amjcard.2015.09.042. Epub 2015 Oct 9. PubMed PMID: 26514302.
15: Probst V, Gourraud JB. Quinidine in Brugada Syndrome: Still a Long Way to
Go…. Circ Arrhythm Electrophysiol. 2015 Dec;8(6):1309-10. doi:
10.1161/CIRCEP.115.003576. PubMed PMID: 26671933.
16: Mikati MA, Jiang YH, Carboni M, Shashi V, Petrovski S, Spillmann R, Milligan
CJ, Li M, Grefe A, McConkie A, Berkovic S, Scheffer I, Mullen S, Bonner M, Petrou
S, Goldstein D. Quinidine in the treatment of KCNT1-positive epilepsies. Ann
Neurol. 2015 Dec;78(6):995-9. doi: 10.1002/ana.24520. Epub 2015 Nov 18. PubMed
PMID: 26369628; PubMed Central PMCID: PMC4811613.
17: Liu L, Collier AC, Link JM, Domino KB, Mankoff DA, Eary JF, Spiekerman CF,
Hsiao P, Deo AK, Unadkat JD. Modulation of P-glycoprotein at the Human
Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission
Tomography Imaging Study. Drug Metab Dispos. 2015 Nov;43(11):1795-804. doi:
10.1124/dmd.114.058685. Epub 2015 Sep 9. PubMed PMID: 26354948; PubMed Central
PMCID: PMC4613948.
18: Doody RS, D'Amico S, Cutler AJ, Davis CS, Shin P, Ledon F, Yonan C, Siffert
J. An open-label study to assess safety, tolerability, and effectiveness of
dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.
CNS Spectr. 2015 Oct 16:1-10. [Epub ahead of print] PubMed PMID: 26471212.
19: Wrighton DC, Muench SP, Lippiat JD. Mechanism of inhibition of mouse Slo3
(KCa 5.1) potassium channels by quinine, quinidine and barium. Br J Pharmacol.
2015 Sep;172(17):4355-63. doi: 10.1111/bph.13214. Epub 2015 Jul 14. PubMed PMID:
26045093; PubMed Central PMCID: PMC4556473.
20: Sokolov AY, Lyubashina OA, Berkovich RR, Panteleev SS. Intravenous
dextromethorphan/quinidine inhibits activity of dura-sensitive spinal trigeminal
neurons in rats. Eur J Pain. 2015 Sep;19(8):1086-94. doi: 10.1002/ejp.631. Epub
2014 Nov 20. PubMed PMID: 25410439.
